Viridian Therapeutics announced the appointment of Tony Casciano to the role of Chief Commercial Officer, CCO. The Company also announced that Chief Operating Officer, COO, Carrie Melvin is no longer with the organization. Casciano, who most recently served as Chief Executive Officer, CEO, and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry. Prior to leading Teal Bio, Casciano spent four years at AMAG Pharmaceuticals, serving initially as Senior Vice President, Head of U.S. Sales and Marketing before ascending to Executive Vice President, COO/CCO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Viridian Therapeutics initiated with a Buy at Stifel
- Viridian Therapeutics price target raised to $40 from $35 at H.C. Wainwright
- Viridian Therapeutics reports Q4 EPS ($1.13), consensus (73c)